Companies Dominating the Leuprolide Acetate Market
- Ferring B.V.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Sun Pharmaceutical Industries Ltd.
- Beijing Biote Pharmaceutical Co., Ltd.
- Anhui Anke Bioengineering (Group) Co., Ltd.
- AbbVie Inc.
- Merck & Co., Inc.
- Taj Pharmaceuticals Limited.
- Zydus Group
- Cipla Inc.
Browse Key Market Insights with Data Illustration:
In the News
- Eugia Pharma Specialties Limited received approval from the US Food and Drug Administration (USFDA) to produce and sell injectable leuprolide acetate which is employed to treat the symptoms of advanced prostate cancer.
- Cipla Inc. introduced Leuprolide Acetate Injection Depot 22.5mg to offer patients in the US high-quality, inexpensive treatments, and enable access to top-notch therapies. Further, it is provided as lyophilized microspheres in a single dose vial as part of a kit that also includes MIXJECT transfer device and a prefilled syringe.
